{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifw2gxebivcspx5byt7u5rcvbb45bzbsqyjcquv7xbe3qjbaaen3a",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mfvjnm3hrzf2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidej4xes5hndtzkge7wnfrwfxnennsehy4wz3lxthjlbsdoxvqjti"
    },
    "mimeType": "image/jpeg",
    "size": 89478
  },
  "path": "/2026/02/27/trump-drug-prices-pharma-mfn-deals-3-year-terms/?utm_campaign=rss",
  "publishedAt": "2026-02-27T20:58:14.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Exclusive",
    "Pharma",
    "Politics",
    "Amgen",
    "Donald Trump",
    "drug pricing",
    "Eli Lilly",
    "Merck",
    "Pfizer",
    "Pharmaceuticals",
    "Sanofi",
    "STAT+",
    "White House"
  ],
  "textContent": "SEC filings show that, at least for some drugmakers, \"most-favored nation\" drug pricing deals with President Trump last three years.",
  "title": "STAT+: Trump most-favored nation drug pricing deals end after three years for some companies",
  "updatedAt": "2026-02-27T21:04:12.000Z"
}